ConductScience.org, home

Comparison · NCT02694744-deaths

Group 1 - Dosing Without Food vs Group 2 - Dosing With Food: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Group 1 - Dosing Without Food vs Group 2 - Dosing With Food: deaths from any cause. Trial comparisons, record NCT02694744-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02694744-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.01750.00310.0929wilson
Risk in group 200.000000000000000006940.0642wilson
Risk difference, group 1 minus group 20.0175-0.04830.0929newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harm, for one more death from any cause on Group 1 - Dosing Without Food than on Group 2 - Dosing With Food57from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Group 1 - Dosing Without FoodPatiromer dosing without food~patiromer: 8.4 g/day starting dose, administered orally157EG000
Group 2Group 2 - Dosing With Food
Patiromer dosing with food~patiromer: 8.4 g/day starting dose, administered orally~\*Note - One randomized participant was excluded from the analysis as this participant did not receive any patiromer dose.
056EG001

Harm

What it counts
Total, all-cause mortality
Time frame
Beginning from the time the subject signs the informed consent form until the subject's last study visit, up to 6 weeks.

Source ClinicalTrials.gov

Trial

Title
Patiromer With or Without Food for the Treatment of Hyperkalemia
NCT number
NCT02694744
Phases
PHASE4
Conditions
Hyperkalemia
Interventions
patiromer
Lead sponsor
Relypsa, Inc.
Results first posted
2017-11-20

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02694744-deaths